Enterprise record

Aspire Biopharma Holdings, Inc. logo

Aspire Biopharma Holdings, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:46a89ced-5fe5-49e7-b64b-a0579129c528Version: public-1As of: unavailable

10 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 3 claims
    • Legal Name: Aspire Biopharma Holdings, Inc. · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026

  2. Aspire Biopharma Holdings, Inc. DEF 14A 2026-02-24

    sec proxy · Source published: Feb 24, 2026 · Retrieved: Apr 25, 2026

    Supports 5 claims
    • Leadership Role: Edward J. Kimball: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Ernest J. Scheidemann, Jr.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Howard Doss: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Kraig T. Higginson: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Philip Balatsos: Director · Claim reviewed: Sep 30, 2026

  3. ASBP 10-K executive officers

    sec filing · Source published: Mar 30, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Leadership Role: Ernest J. Scheidemann, Jr.: Chief Financial Officer · Claim reviewed: Sep 30, 2026
    • Leadership Role: Kraig T. Higginson: Chief Executive Officer · Claim reviewed: Sep 30, 2026